-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
A few days ago, Sanofi announced the data of the third phase of Dupixent in moderate to severe chronic spontaneous urticaria
Clinically, doctors usually use antihistamines or Roche Xolair to treat this disease, but many patients’ conditions still cannot be effectively controlled
Sibold said Dupixent has the "right characteristics" for success in the field of chronic spontaneous urticaria, because the drug has good safety characteristics and allows patients to self-administer and manage the disease at home
Dupixent was approved by the FDA at the end of March 2017 and has been approved to treat a variety of diseases caused by type 2 inflammation: moderate to severe atopic dermatitis (patients ≥ 6 years old), moderate to severe asthma (≥ 12 years old) patients), chronic rhinosinusitis with nasal polyps - sinusitis (CRSwNP, adult patients) and so on
In terms of atopic dermatitis and the other two types of inflammation, Dupixent’s revenue in the second quarter of 2021 was 1.
In addition to the star drug Dupixent, vaccines are another key part of the company's strategy.
According to the company’s latest financial report for the second quarter of 2021, Sanofi’s second-quarter net sales were 8.
Sanofi will use the surplus funds to invest in its business to help drive its growth momentum
Reference source: Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria
